BLENDS / DIRECT CATALOG PRICING
GLOW Blend
GLOW Blend is a vendor mixture described in the catalog as BPC-157, TB-500, and GHK-Cu totaling 70 mg. Component ratios, exact TB-500 sequence, salts, and analytical specification are not provided.
- Format
- Lyophilized research vial
- Listed formats
- 1
- Available now
- 1
- Catalog class
- Blends
- 70 mg$64.00 · AvailableSelect
Pricing, availability, quantity tiers, and member eligibility are checked again when an order is submitted.
TECHNICAL OVERVIEW
Identity first, claims kept in scope.
GLOW Blend is a vendor mixture described in the catalog as BPC-157, TB-500, and GHK-Cu totaling 70 mg. Component ratios, exact TB-500 sequence, salts, and analytical specification are not provided.
The blends classification supports catalog navigation; it does not establish efficacy, safety, approval, human use, or equivalence to a material used in a cited study.
SPECIFICATIONS
- Material class
- Blends
- Physical format
- Lyophilized vial
- Research status
- Research purposes only
- Commerce status
- 1 format currently orderable
PLAIN-LANGUAGE RESEARCH SNAPSHOT
What researchers have actually studied.
GLOW Blend is a vendor mixture described in the catalog as BPC-157, TB-500, and GHK-Cu totaling 70 mg. Component ratios, exact TB-500 sequence, salts, and analytical specification are not provided.
- Research covered
- Component-level literature includes preclinical GHK-Cu wound/fibroblast work and predominantly preclinical BPC-157 literature. No authoritative study of the exact three-component, 70 mg GLOW formulation was identified.
- Important limit
- Evidence for individual ingredients cannot demonstrate interaction, stability, exposure, or outcomes for the mixture. The exact composition is incomplete and the trade-name blend is not independently verifiable from catalog text.
FACTUAL FAQ
GLOW Blend catalog questions
What formats are currently listed?
70 mg. Current price and stock state appear above.
What did researchers study?
Component-level literature includes preclinical GHK-Cu wound/fibroblast work and predominantly preclinical BPC-157 literature. No authoritative study of the exact three-component, 70 mg GLOW formulation was identified.
What is the most important evidence limit?
Evidence for individual ingredients cannot demonstrate interaction, stability, exposure, or outcomes for the mixture. The exact composition is incomplete and the trade-name blend is not independently verifiable from catalog text.
How should this listing be interpreted?
It is a research-material catalog listing, not medical guidance, a dosage recommendation, a safety or efficacy claim, or evidence of regulatory approval.
Where can I review related scientific references?
Use the PSC research library to locate general and compound-related source material. Open related research references →
